Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study

Area of Science:

• Neurology
• Pharmacology
• Movement Disorders

Background:

• Levodopa-carbidopa intestinal gel (LCIG) is a treatment for advanced Parkinson's disease (APD).
• It is administered directly to the small intestine to stabilize levodopa plasma levels.
• The COSMOS study investigated LCIG's impact on polypharmacy in APD patients.

Purpose of the Study:

• To evaluate the efficacy of LCIG in reducing the need for multiple medications in APD patients.
• To assess the rate of LCIG monotherapy over time.
• To analyze changes in 'off' time and dyskinesia duration.

Main Methods:

• The COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS) was a multinational observational study.
• Data were collected cross-sectionally and retrospectively from patients using LCIG for at least 12 months.
• The primary endpoint was the percentage of patients on LCIG monotherapy at various time points post-initiation.

Main Results:

• 409 patients from 14 countries were enrolled, with a mean LCIG treatment duration of 35.8 months.
• 15.2% of patients initiated LCIG as monotherapy, rising to 31.7% at 12 months.
• Mean 'off' time and dyskinesia duration decreased significantly across monotherapy and polytherapy groups.

Conclusions:

• LCIG is an effective long-term monotherapy for APD.
• LCIG contributes to reduced polypharmacy in APD patients.
• The treatment demonstrates a favorable risk-benefit profile.